Sign up to save your podcasts
Or
Share AI Access Brief Podcast
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
AI Access Brief Podcast
AI Access Brief Podcast episodes
- Avacopan Crisis, D-VRd Reversal, Mirvetuximab AccessEpisode 33 — 17 June 2026Episode 33 covers NICE's interim CDF recommendation for mirvetuximab soravtansine in platinum-resistant ovarian cancer, the D-VRd reversal and what it signals about population-segmented cost-effectiveness modelling, the convergent avacopan regulatory crisis spanning MHRA, NEJM, PRAC and FDA, and the PRAC's valproate paternal exposure conclusion — a precedent-setting decision to maintain precautions despite explicitly inconsistent evidence.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast13 min
- JCA Devices Live, Camizestrant Divergence, JSC Window OpenEpisode 32 — 17 June 2026Episode 32 covers the publication of the tovorafenib JCA report and what its procedural timeline means for submission planning, the operational launch of medical device JCAs in June 2026, the newly opened JSC window, and the camizestrant case — where the EMA and FDA have reached categorically different conclusions from the same dataset, creating one of the most complex active HEOR files in oncology.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast12 min
- PRAC Valproate Review, JCA Scale-Up, Emergency Trial GuidanceEpisode 31 — 15 June 2026EMA's PRAC concludes valproate neurodevelopmental risk remains uncertain while EU JCA programme scales to 50 assessments in 2026. Emergency clinical trial guidance opens for consultation as oral GLP-1 approvals expand market access complexity.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast6 min
- EU JCA Medical Devices Launch, MHRA-NICE First GuidanceEpisode 30 — 14 June 2026The EU JCA framework expands into medical devices this month while MHRA-NICE alignment delivers its first coordinated guidance. Europe's HTA infrastructure shows sustained momentum across multiple operational tracks.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast5 min
- MHRA-NICE Aligned Pathway and EU JCA OperationalizationEpisode 29 — 13 June 2026The UK's MHRA-NICE aligned pathway delivers first guidance this month with 27 early adopter companies, while the EU publishes its second JCA report on tovorafenib. These developments signal coordinated evolution in European HEOR infrastructure prioritizing accelerated patient access.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast6 min
- First JCA Published, CHMP Patterns, Device ExpansionEpisode 28 — 12 June 2026The EU published its first joint clinical assessment report for tovorafenib, marking a milestone in HTA coordination. CHMP approval patterns show a pipeline increasingly skewed toward rare diseases and indication extensions over novel molecules.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast7 min
- First JCA Report and Oral Semaglutide ApprovalEpisode 27 — 10 June 2026The EU published its first Joint Clinical Assessment report for tovorafenib while EMA approved oral semaglutide for weight management. JCA capacity constraints emerge as demand for scientific advice exceeds available slots.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast6 min
- CHMP Pipeline Shift and Critical Medicines Act MandatesEpisode 26 — 09 June 2026CHMP's May approvals reveal a structural shift toward rare disease development while the Critical Medicines Act introduces mandatory supply chain transparency requirements. AI maintains its dominance in HEOR methodology as NICE expands cardiovascular and digital health guidance.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast6 min
- Medical Device JCAs Launch and Novel Mechanism ApprovalsEpisode 25 — 08 June 2026Medical device Joint Clinical Assessments begin in June 2026 as the EU HTA Regulation expands beyond oncology medicines. FDA approves first-in-class aldosterone synthase inhibitor baxdrostat while ISPOR signals a shift toward evidence judgment over generation.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast6 min
- NICE Diabetes Revolution, EU Device JCAs, Clinical Trial AccelerationEpisode 24 — 07 June 2026NICE's revolutionary diabetes guideline makes SGLT-2 inhibitors first-line therapy while EU HTA regulation expands to high-risk medical devices. FDA accelerated approvals surge and EU clinical trial acceleration shows early progress toward 2030 targets.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast5 min
About AI Access Brief Podcast
From the publisher's feed
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and…
evidence strategy.